Ready-to-use Dynabeads™ will allow you to optimize ex vivo T cell activation and proliferation in translational research, while preserving T cell viability and optimal immune function. Simultaneous signaling to TCR/CD3 and CD28 triggers a physiological activation and expansion of human T cells. You can also stimulate and expand human antigen–specific T cell lines or clones using Dynabeads™ Human T-Activator CD3/CD28/CD137 

This simple, efficient and consistent technology out-performs and replaces traditional home-brew methods for generic activation based on antigen-presenting cells (APCs), mitogens (e.g. ConA, PHA), soluble/plate-bound antibodies, or chemical activators, and is well documented in the published literature. Expansion and re-infusion of genetically engineered T cells has the potential to revolutionize the treatment of leukemia and related blood cancers. A clinical research grade version is also available, allowing you to move from mouse studies to clinical research using the same technology platform.

Which human T Cell activation/expansion product is right for you?

Activation and expansion of polyclonal T cells Activation and expansion of regulatory T cells Expansion of antigen-specific T cells Isolation and expansion of polyclonal T cells cGMP-grade beads for isolation and expansion of polyclonal T cells
Order Now Order Now Order Now Order Now Order Now
Dynabead™ Human
T-Activator CD3/CD28
Dynabeads™ Human Treg Expander Dynabeads™ Human T-Activator CD3/CD28/CD137
Dynabeads™ Human T-Expander CD3/CD28 Dynabeads™ CD3/CD28 CTS™
Research grade Research grade Research grade Research grade Research-grade version of the cGMP-grade product For research use or non-commercial manufacturing of cell-based products for clinical research
Starting samples Pure T cells isolated from any sample Pure regulatory T cells isolated from any sample T cell lines or T cell clones Pure T cells isolated from any sample, preferrably from cryopreserved human PBMC Cryopreserved human PBMC obtained from leukapheresis product
No. of cells processed 4 x 107 cells /
mL beads
5 x 106 cells / mL beads 5 x 106 cells / mL beads 3.3 x 107 cells / mL beads 1.6 x 108 cells / mL beads
Bead:T cell ratio for activation
/expansion
1:1 4:1 1:10 3:1 3:1
Applications Short-term activation or expansion of polyclonal T cells without the need for feeder cells for use in e.g., transfection/ transduction, T cell receptor signaling, proteomics. Short-term activation or expansion of pre-isolated regulatory
T cells without the need for feeder cells e.g., for use in flow cytomery, MLR, proteomics, gene expression.
Expansion of antigen-specific
T cells without the use of feeder cells e.g., for use in flow cytometry, phenotyping, adoptive transfer.
Isolation and expansion of CD3+
T cells, or expansion of pre-isolated T cells or T cell subsets without the need for feeder cells.
Isolation and expansion of CD3+
T cells or expansion of pre-isolated T cells or T cell subsets without the need for feeder cells.
Shelf life from production date 2 years 2 years 2 years 2 years 2 years
Required materials Magnets: magnets+ rIL-2 (for expansion) Magnets: magnets+ rIL-2 (for expansion) Magnets: magnets
+ rIL-2
Magnets: DynaMag™ CTS Magnet (Cat. No. 12102),
or visit magnets
+ rIL-2
Magnets: DynaMag™ CTS Magnet (Cat. No. 12102), or visit magnets+ rIL-2

References

The references listed below are among the many published papers documenting the performance of the Dynabeads® technology for T cell activation and expansion:

  1. Porter, D.L. et al. (2011) Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia. N Engl J Med 2011; 365:725-733.
  2. Kalos M. et al. (2011) T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia. Sci. Transl. Med. 3, 95ra73 
  3. Berger, C. et al. (2003) CD28 costimulation and immunoaffinity-based selection efficiently generate primary gene-modified T cells for adoptive immunotherapy. Blood 101:476–484.
  4. Bonyhadi, M. et al. (2005) In vitro engagement of CD3 and CD28 corrects T cell defects in chronic lymphocytic leukemia. J Immunol 174:2366–2375.
  5. Hami, L. et al. (2003) Comparison of a static process and a bioreactor-based process for the GMP manufacture of autologous Xcellerated T cells for clinical trials. BioProcessing Journal Vol. 2 No. 6, November/December 2003.
  6. Levine, B.L. et al. (2002) Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreases CCR5 expression in HIV infection. Nat Med 8:47–53.
  7. Godfrey, W.R. et al. (2004) In vitro expanded human CD4+CD25+ T regulatory cells can markedly inhibit allogeneic dendritic cell stimulated MLR cultures. Blood 104:453–461.
  8. Coito, S. et al. (2004) Retrovirus-mediated gene transfer in human primary T lymphocytes induces an activation-and transduction/selection-dependent TCRBV repertoire skewing of gene-modified cells. Stem Cells Dev 13:71–81.
  9. Rapoport, A.P. et al. (2005) Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med 11:1162–1163.